原发性肝癌血供特点与经导管肝动脉化疗栓塞治疗研究进展  

Research Progress on Blood Supply Characteristics and Transcatheter Arterial Chemoembolization Treatment of Primary Hepatocellular Carcinoma

作　　者：全雨欣 白云[1] 董立华[2] QUAN Yu-xin;BAI Yun;DONG Li-hua(West China School of Medicine,Sichuan University,Chengdu 610041,China;West China School of Basic Medical Sciences and Forensic Medicine,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学临床医学院,成都610041 [2]四川大学华西基础与法医学院,成都610041

出　　处：《四川解剖学杂志》2022年第2期157-159,共3页Sichuan Journal of Anatomy

摘　　要：原发性肝癌的(PHC)发病率和致死率极高,是目前最难治疗的肿瘤之一.经导管肝动脉化疗栓塞(TACE)通过导管选择性插入肿瘤供血动脉并经导管灌注化疗药物或栓塞药物达到使肿瘤坏死的目的,是肝癌非手术治疗的首选方案.但由于肝癌血供的丰富性及不确定性,目前TACE的治疗存在盲目性,效果并不理想.对原发性肝癌供血的深入研究,对于提高TACE治疗及多学科联合治疗的疗效,有着重要意义.本文通过分析原发性肝癌的供血途径,为原发性肝癌患者的治疗提供科学的建议.Primary hepatocellular carcinoma(PHC)is one of the most difficult tumors to treat because of its high incidence and mortality.Transcatheter arterial chemoembolization(TACE)is the first choice for non-surgical treatment of liver cancer.However,due to the richness and the uncertainty of the blood supply of PHC,the embolization chemotherapy of TACE is blind at present,and the effect is not ideal.It is of great significance to study the blood supply of PHC in order to improve the curative effect of TACE treatment and multi-disciplinary combined therapy.It will provide scientific suggestions for the treatment of PHC by analyzing the blood supply route of PHC.

关 键 词：原发性肝癌 经导管肝动脉化疗栓塞 血供 

分 类 号：R735.7[医药卫生—肿瘤]